In the treatment of B-cell lymphomas and leukemias and increasingly in the treatment of autoimmune diseases, the inhibition of the main signaling pathway of B cells, the BCR pathway, plays a crucial role. Here, BCR is linked to B-cell non-Hodgkin lymphoma.